It has been reported that EZH2 directly inhibits miR-29, miR-26, miR-101, and miR-30 families in B cell lymphomas, chronic lymphocytic leukemia, hepatocellular carcinoma, malignant peripheral nerve sheath tumor cells, and prostate cancer 33, 36, 52-54. Here, EZH2 is linked to prostate carcinoma.